KOREA WHO

Kee Woo-sung is the Vice Chairman and CEO of Celltrion.

He has focused on expanding Celltrion’s core biosimilar (biopharmaceutical generic drug) business while enhancing the company’s new drug development capabilities.

He was born on December 10, 1961 (lunar calendar).

Kee graduated from Joongdong High School in Seoul and Hanyang University with a degree in Industrial Engineering.

He began his professional career in the planning department at Daewoo Motors.

When Seo Jung-jin, the Chairman of Celltrion, founded Nexol, the predecessor of Celltrion, Kee joined and served as the Head of Production Management, Chief Secretary, and Vice President.

He progressed to become Celltrion’s Senior Executive Vice President, President, and was later appointed Co-CEO before being promoted to Vice Chairman in 2018.

In December 2023, following the merger of Celltrion and Celltrion Healthcare, the integrated Celltrion was launched, with a three-person CEO structure comprising Seo Jin-seok, Chairman of the Celltrion Board of Directors, Kim Hyung-ki, Vice Chairman of Celltrion, and Kee Woo-sung.

Kee is considered one of Chairman Seo Jung-jin's closest associates.

During his tenure as Head of Celltrion’s Product Development Division, he laid the foundation for Celltrion by developing "Remsima," an autoimmune disease treatment.

He is known for his strong spirit of challenge and places great importance on leadership that inspires passion among employees.

#Celltrion #KeeWooSung #biosimilar #biopharmaceutical #Remsima #leadership #SeoJungJin #drugdevelopment #healthcaremerger #biotech